DIA 2020 Global Annual Meeting

This event is now offered in a new entirely virtual format.

Back to Agenda

Drug Pricing in the United States: How and Why is it Different Than in the Rest of the World

Session Chair(s)

Christopher Marrone, PharmD, RPh

Outcomes Liaison Advisor – National Accounts, Value, Evidence and Outcomes (VEO)

Eli Lilly and Company, United States

Drug Pricing in the United States continues to be a hotly debated subject. As candidates head into the US 2020 election, the topic will only garner more attention. This session will review the differences in worldwide drug pricing regulations and practices. The future landscape of drug pricing in the United States will be discussed, with a review of drug pricing proposals.

Learning Objective : Compare US and non-US drug pricing regulations; Discuss the future landscape of US drug pricing;

Speaker(s)

Global Perspective: Benchmarking Prescription Drug Price and Access Around the World

Scott Roberts, MBA

Citrus Health Group, United States

Managing Partner

Pharmaceutical Pricing in the US Healthcare Market

Johann Odermann

JustSo Marketing, United States

Principal

Patient Affordability: Caught at the Intersection of Manufacturer and “System” Dynamics in Specialty Products

Aria Cohen, MBA

Apellis Pharmaceuticals, United States

Senior Director, US Market Access

Have an account?